Combination products provide new avenues for the development of improved drug-drug, drug-device products, as well as generating opportunities for companies to leverage their existing products & patent life. This forum will focus on the development challenges, commercial and partnering strategies, as well as the market implications of combination products.
According to Pharmaceutical Technology, there has been a surge in the number of combination product (i.e. where a drug product is combined with a medical device) launches in recent years and this trend is set to continue as more companies seek to extend the life of existing branded medicines.
CoreRx, fast becoming a world-recognized leader in early drug contract development, was announced today as one of Tampa Bay’s Fast 50 companies. The Tampa Bay Business Journal’s Fast 50 is a list of the fastest growing privately held companies in Tampa Bay over a span of three years. Last year, CoreRx was recognized as the 6th fastest growing company in the Tampa Bay region.